In the presentation, Frandsen emphasized the importance of the clinical proof-of-concept and Phase III validation of the Company's ExpreS2[TM] technology within the Bavarian Nordic sponsored COVID-19 vaccine program, ABNCoV2. This proof-of-concept and validation is of paramount importance for ExpreS[2]ion as it confirms the efficacy and safety of a product based on the Company's technology for the first time in a pivotal clinical setting. This is a positive indicator for other vaccines based on the ExpreS2[TM] technology.

• Monetization of focus pipeline assets, primarily ES2B-C001 through partnering and ABNCoV2 through license income
• Financing of new initiatives via non-dilutive financing
• Develop pipeline towards major value inflection points
• Strengthen the intellectual property rights and extract value from proprietary vaccine technologies
• Exploratory pipeline to build new internal assets in vaccine markets with unmet needs
• Focus on partnering activities for financing & risk sharing of assets

Finally, in the oral commentary it was clarified that the Company, with the recently announced strategic review, aims to extend its base case cash runway beyond 2024.

The presentation can be found on the Company's investor website via the following link:  https://investor.expres2ionbio.com/presentations/

Certified Adviser
Svensk Kapitalmarknadsgranskning AB